dalteparin has been researched along with Coronary Artery Disease in 41 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach." | 9.10 | Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002) |
| "The mainstay of treatment for unstable coronary artery disease (UCAD) currently consists of antithrombotic therapy with aspirin plus unfractionated heparin (UFH), together with anti-ischemic treatment with beta blockers and nitrates." | 6.19 | Long-term management--the way forward? ( Wallentin, L, 2000) |
| "The FRISC II trial demonstrated that, for patients with unstable coronary artery disease, an early invasive strategy following acute treatment with dalteparin and aspirin, was superior to a more conservative approach." | 5.10 | Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. ( Husted, SE; Kontny, F; Lagerqvist, B; Ståhle, E; Swahn, E; Wallentin, L, 2002) |
| "On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes." | 4.81 | Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
| "Hyperkalemia is an infrequent but potentially serious complication of low molecular weight heparin (LMWH) use." | 2.79 | Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial. ( Bramlage, P; Melzer, N; Michaelis, HC, 2014) |
| "Myeloperoxidase (MPO), a leukocyte-derived heme enzyme binds to the endothelium and depletes vascular nitric oxide (NO) bioavailability in animal models." | 2.75 | Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. ( Baldus, S; Heitzer, T; Klinke, A; Lau, D; Meinertz, T; Rudolph, TK; Rudolph, V; Szoecs, K; Witte, A, 2010) |
| "Although weight-based nomograms have improved the efficacy and safety of dosing unfractionated heparin in ST-segment elevation myocardial infarction, achieving therapeutic anticoagulation in practice remains challenging." | 2.74 | Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. ( Antman, EM; Cheng, S; Morrow, DA; Sabatine, MS; Sloan, S, 2009) |
| " The elimination half-life was thus estimated to be 6." | 2.71 | Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ( Ankri, A; Bouzamondo, A; Hulot, JS; Lechat, P; Mahé, I; Montalescot, G; Urien, S; Vantelon, C, 2004) |
| "Diabetes mellitus is a major contributor to CAD." | 2.71 | Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. ( Diderholm, E; Lagerqvist, B; Lindahl, B; Malmberg, K; Norhammar, A; Rydén, L; Wallentin, L, 2004) |
| "5 mg/kg intravenous (IV), and eptifibatide using the ESPIRIT dosing (180 g/kg bolus IV, immediately followed by a 2 g/kg/minute continuous IV infusion, and then a second 180 g/kg bolus IV ten minutes after the first bolus)." | 2.70 | Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. ( Bertolet, BD; Gupta, A; Miller, L, 2002) |
| " To confront these challenges, cardiologists committed to the continued use of LMWH must develop safe and user-friendly approaches to transition patients from the noninvasive to invasive settings." | 2.45 | Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. ( Bullock-Palmer, RP; Cavusoglu, E; Marmur, JD; Poludasu, S, 2009) |
| "Fondaparinux was administered to 18 patients at a dose of 1 × 2." | 1.62 | A study of anticoagulant therapy in patients with coronary artery disease. ( Ardiana, M; Hartono, R; Hasmono, D; Puspitasari, AD; Salean, DDC, 2021) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | 1.35 | The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| " dosing regimens is not clearly established." | 1.33 | Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ( Ankri, A; Choussat, R; Collet, JP; Hulot, JS; Lechat, P; Montalescot, G; Sanchez-Pena, P; Urien, S, 2005) |
| " IV dosing consistently achieved adequate anticoagulation." | 1.32 | Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. ( Alt, EU; Cheong, BY; Díez, JG; O'Meallie, LP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (63.41) | 29.6817 |
| 2010's | 13 (31.71) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Arantes, FBB | 1 |
| Menezes, FR | 1 |
| Franci, A | 1 |
| Barbosa, CJDG | 1 |
| Dalçoquio, TF | 1 |
| Nakashima, CAK | 1 |
| Baracioli, LM | 1 |
| Furtado, RHM | 1 |
| Nomelini, QSS | 1 |
| Ramires, JAF | 1 |
| Kalil Filho, R | 1 |
| Nicolau, JC | 1 |
| Puspitasari, AD | 1 |
| Salean, DDC | 1 |
| Hasmono, D | 1 |
| Hartono, R | 1 |
| Ardiana, M | 1 |
| Li, ZZ | 1 |
| Tao, Y | 1 |
| Wang, S | 1 |
| Yin, CQ | 1 |
| Gao, YL | 1 |
| Cheng, YT | 1 |
| Li, Z | 1 |
| Ma, CS | 1 |
| Voudris, V | 1 |
| Georgiadou, P | 1 |
| Kalogris, P | 1 |
| Kostelidou, T | 1 |
| Karabinis, A | 1 |
| Gerotziafas, G | 1 |
| Nenna, A | 1 |
| Spadaccio, C | 1 |
| Prestipino, F | 1 |
| Lusini, M | 1 |
| Sutherland, FW | 1 |
| Beattie, GW | 1 |
| Petitti, T | 1 |
| Nappi, F | 1 |
| Chello, M | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Pleym, H | 1 |
| Wahba, A | 1 |
| Bjella, L | 1 |
| Stenseth, R | 1 |
| Rudolph, TK | 1 |
| Rudolph, V | 1 |
| Witte, A | 1 |
| Klinke, A | 1 |
| Szoecs, K | 1 |
| Lau, D | 1 |
| Heitzer, T | 1 |
| Meinertz, T | 1 |
| Baldus, S | 1 |
| Cheng, S | 1 |
| Morrow, DA | 1 |
| Sloan, S | 1 |
| Antman, EM | 3 |
| Sabatine, MS | 1 |
| Marmur, JD | 1 |
| Bullock-Palmer, RP | 1 |
| Poludasu, S | 1 |
| Cavusoglu, E | 1 |
| Montalescot, G | 3 |
| Ellis, SG | 1 |
| de Belder, MA | 1 |
| Janssens, L | 1 |
| Katz, O | 1 |
| Pluta, W | 1 |
| Ecollan, P | 1 |
| Tendera, M | 1 |
| van Boven, AJ | 1 |
| Widimsky, P | 1 |
| Andersen, HR | 1 |
| Betriu, A | 1 |
| Armstrong, P | 1 |
| Brodie, BR | 1 |
| Herrmann, HC | 1 |
| Neumann, FJ | 1 |
| Effron, MB | 1 |
| Lu, J | 1 |
| Barnathan, ES | 1 |
| Topol, EJ | 1 |
| Goodman, SG | 3 |
| Bakaeen, FG | 1 |
| Chow, M | 1 |
| Ghadir, M | 1 |
| Albo, D | 1 |
| Berger, DH | 1 |
| Chu, D | 1 |
| Bertel, O | 1 |
| Ramsay, D | 1 |
| Wettstein, T | 1 |
| Kurz, DJ | 1 |
| Stettler, I | 1 |
| Straumann, E | 1 |
| Frielingsdorf, J | 1 |
| Maurer, D | 1 |
| Naegeli, B | 1 |
| Kvasnička, J | 1 |
| Horák, J | 1 |
| Zenáhlíková, Z | 1 |
| Kvasnička, T | 1 |
| Simek, S | 1 |
| Kovárník, T | 1 |
| Malíková, I | 1 |
| Linhart, A | 1 |
| Aschermann, M | 1 |
| Chen, WH | 1 |
| Lau, CP | 1 |
| Lau, YK | 1 |
| Ng, W | 1 |
| Lee, PY | 1 |
| Yu, CM | 1 |
| Ma, E | 1 |
| Aggarwal, A | 1 |
| Sobel, BE | 1 |
| Schneider, DJ | 1 |
| Monroe, VS | 1 |
| Kerensky, RA | 1 |
| Rivera, E | 1 |
| Smith, KM | 1 |
| Pepine, CJ | 1 |
| Hulot, JS | 2 |
| Vantelon, C | 1 |
| Urien, S | 2 |
| Bouzamondo, A | 1 |
| Mahé, I | 1 |
| Ankri, A | 2 |
| Lechat, P | 2 |
| Díez, JG | 1 |
| Cheong, BY | 1 |
| O'Meallie, LP | 1 |
| Alt, EU | 1 |
| Sanchez-Pena, P | 1 |
| Collet, JP | 1 |
| Choussat, R | 1 |
| Cohen, M | 1 |
| Mahaffey, KW | 1 |
| Pieper, K | 1 |
| Pollack, CV | 1 |
| Hoekstra, J | 1 |
| Langer, A | 1 |
| Col, JJ | 1 |
| White, HD | 1 |
| Califf, RM | 1 |
| Ferguson, JJ | 1 |
| Cannon, CP | 1 |
| Bhatt, DL | 1 |
| Rizos, I | 1 |
| Tsiodras, S | 1 |
| Rigopoulos, AG | 1 |
| Dragomanovits, S | 1 |
| Kalogeropoulos, AS | 1 |
| Papathanasiou, S | 1 |
| Sakadakis, EA | 1 |
| Kremastinos, DT | 1 |
| Noviasky, JA | 1 |
| Gaffney, BJ | 1 |
| Fox, KA | 1 |
| Miller, L | 1 |
| Gupta, A | 1 |
| Bertolet, BD | 1 |
| Massel, D | 1 |
| Cruickshank, MK | 1 |
| Becker, RC | 1 |
| Spencer, FA | 1 |
| Gibson, M | 1 |
| Rush, JE | 1 |
| Sanderink, G | 1 |
| Murphy, SA | 1 |
| Ball, SP | 1 |
| Pathania, YS | 1 |
| Md, AB | 1 |
| Melzer, N | 1 |
| Bramlage, P | 1 |
| Michaelis, HC | 1 |
| Grassman, ED | 1 |
| Leya, F | 1 |
| Fareed, J | 1 |
| Lewis, BE | 1 |
| Bacher, P | 1 |
| Loeb, HS | 1 |
| Moran, JF | 1 |
| Dangas, G | 1 |
| Iakovou, I | 1 |
| Inamo, Y | 1 |
| Saito, K | 1 |
| Hasegawa, M | 1 |
| Hayashi, R | 1 |
| Nakamura, T | 1 |
| Abe, O | 1 |
| Ishikawa, T | 1 |
| Yoshino, Y | 1 |
| Hashimoto, K | 1 |
| Fuchigami, T | 1 |
| Niemi, T | 1 |
| Silvasti-Lundell, M | 1 |
| Armstrong, E | 1 |
| Hernesniemi, J | 1 |
| Verheugt, FW | 1 |
| Husted, SE | 1 |
| Wallentin, L | 4 |
| Lagerqvist, B | 2 |
| Kontny, F | 1 |
| Ståhle, E | 1 |
| Swahn, E | 2 |
| Janzon, M | 1 |
| Levin, LA | 1 |
| Norhammar, A | 1 |
| Malmberg, K | 1 |
| Diderholm, E | 1 |
| Lindahl, B | 1 |
| Rydén, L | 1 |
| Oldgren, J | 1 |
| Fellenius, C | 1 |
| Boman, K | 1 |
| Jansson, JH | 1 |
| Nilsson, TK | 1 |
| Siegbahn, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| Effects of LMWH Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT02389582] | Phase 4 | 29 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention [NCT00046228] | Phase 3 | 2,461 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention[NCT03145675] | Phase 4 | 378 participants (Actual) | Interventional | 2017-05-12 | Completed | ||
| A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)[NCT00043784] | Phase 3 | 8,000 participants | Interventional | 2001-08-31 | Completed | ||
| Prevalence of the Appearance of Diabetic Ulcers, After the Manufacture and Adaptation of Personalized Insoles, With Monitoring of Temperature and Plantar Pressure in Diabetic Patients[NCT05843929] | 86 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality through 1 year from randomization. (NCT00046228)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 56 |
| Abciximab Facilitated PCI Group | 60 |
| Reteplase/Abciximab Facilitated PCI Group | 52 |
All cause mortality occurred through 90 days from randomization. (NCT00046228)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 36 |
| Abciximab Facilitated PCI Group | 45 |
| Reteplase/Abciximab Facilitated PCI Group | 43 |
The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization. (NCT00046228)
Timeframe: 90 Days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 72 |
| Abciximab Facilitated PCI Group | 61 |
| Reteplase/Abciximab Facilitated PCI Group | 61 |
(NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 139 |
| Abciximab Facilitated PCI Group | 178 |
| Reteplase/Abciximab Facilitated PCI Group | 271 |
All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee). (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 1 |
| Abciximab Facilitated PCI Group | 0 |
| Reteplase/Abciximab Facilitated PCI Group | 5 |
Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participant (Number) |
|---|---|
| Primary PCI Group | 55 |
| Abciximab Facilitated PCI Group | 81 |
| Reteplase/Abciximab Facilitated PCI Group | 118 |
Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 128 |
| Abciximab Facilitated PCI Group | 122 |
| Reteplase/Abciximab Facilitated PCI Group | 120 |
Severe thrombocytopenia is defined as platelet count < 50,000 cells/μL. (NCT00046228)
Timeframe: Discharge/Day 7
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 11 |
| Abciximab Facilitated PCI Group | 16 |
| Reteplase/Abciximab Facilitated PCI Group | 16 |
(NCT00046228)
Timeframe: 60 to 90 minutes
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 75 |
| Abciximab Facilitated PCI Group | 85 |
| Reteplase/Abciximab Facilitated PCI Group | 108 |
Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring > 48 hours after randomization). (NCT00046228)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Primary PCI Group | 86 |
| Abciximab Facilitated PCI Group | 86 |
| Reteplase/Abciximab Facilitated PCI Group | 81 |
4 reviews available for dalteparin and Coronary Artery Disease
| Article | Year |
|---|---|
Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Coronary Artery Disease; Da | 2009 |
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Art | 2003 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
16 trials available for dalteparin and Coronary Artery Disease
| Article | Year |
|---|---|
Effect of Preoperative Aspirin Replacement With Enoxaparin in Patients Undergoing Primary Isolated On-Pump Coronary Artery Bypass Grafting.
Topics: Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relati | 2016 |
Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function.
Topics: Aged; Biological Availability; Cholesterol, HDL; Coronary Artery Disease; Double-Blind Method; Endot | 2010 |
Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Coronary Artery Disease; Coronary Thromb | 2009 |
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Confidence Intervals; Coronary Artery Disease; Enoxa | 2010 |
Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS).
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Disease; Dose-Response Relationship, Drug; Enoxapari | 2010 |
Reduced thrombin generation and soluble P-selectin after intravenous enoxaparin during PCI.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; En | 2011 |
Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Artery Disease; Creati | 2004 |
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
Topics: Aged; Coronary Artery Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middl | 2006 |
Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2002 |
Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Double-Blind Method; Female; Heparin, Low-Molecular-W | 2014 |
A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Dise | 2001 |
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
Topics: Coronary Artery Disease; Dalteparin; Double-Blind Method; Female; Fibrinolytic Agents; Hemorrhage; H | 2002 |
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Coronary Artery Disease; Cost-Benefit Analysis; Dalt | 2003 |
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
Topics: Aged; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dalteparin; Diabetes Co | 2004 |
Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
Topics: Aged; Anticoagulants; Blood Coagulation; C-Reactive Protein; Coronary Artery Disease; Dalteparin; Do | 2005 |
Long-term management--the way forward?
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Drug Therapy, Combin | 2000 |
22 other studies available for dalteparin and Coronary Artery Disease
| Article | Year |
|---|---|
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular | 2020 |
A study of anticoagulant therapy in patients with coronary artery disease.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Fondaparinux; Humans; Male; Middle Aged; | 2021 |
Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Female; Heparin; Humans; Male; Middle Age | 2018 |
Missed Heparin-Induced Thrombocytopenia (HIT) Diagnosis in a Patient with Acute Stent Thrombosis.
Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Heparin; Humans; Male; Percutaneous Coron | 2019 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Sonoclot analysis in coronary artery surgery: a comparison between patients with unstable coronary artery disease treated with enoxaparin before surgery and patients with stable coronary artery disease not treated with enoxaparin.
Topics: Aged; Anticoagulants; Blood Coagulation Tests; Coronary Artery Bypass; Coronary Artery Disease; Enox | 2008 |
Does enoxaparin have enough FINESSE to replace unfractionated heparin in primary percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Coronary Restenosis; Enoxap | 2010 |
Ruptured colonic intramural hematoma with massive hemorrhage after aortic valve replacement.
Topics: Aortic Valve Stenosis; Coronary Artery Bypass; Coronary Artery Disease; Enoxaparin; Fibrinolytic Age | 2010 |
Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; China; Combined Modality Therapy; Coronary Art | 2002 |
Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Coronary Artery Disease; Drug Evaluation; Enoxaparin; F | 2002 |
Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Case-Control Studies; Coronary Artery Disease; Drug | 2004 |
Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography | 2005 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2006 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
The "superiority" of enoxaparin for treatment of acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Clinical Trials as Topic; Coronary Artery Disease; Enoxaparin; Hepari | 2001 |
Enoxaparin treatment in unstable coronary artery disease: international cost savings.
Topics: Anticoagulants; Coronary Artery Disease; Enoxaparin; Humans | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
Acral hemorrhagic blisters induced by reviparin.
Topics: Anticoagulants; Blister; Coronary Artery Disease; Fingers; Foot; Heparin, Low-Molecular-Weight; Huma | 2019 |
The end of systemic anticoagulation therapy for restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Coronary Artery Disease; Coronary Restenosi | 2001 |
Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.
Topics: Anticoagulants; Chemotherapy, Adjuvant; Child, Preschool; Coronary Artery Disease; Dalteparin; Femal | 2014 |
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome; | 2009 |
Low molecular weight heparin: a bridge over troubled water.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Dalteparin; Heparin, Low-Molecular-Weight; Humans; | 2002 |